Healthcare distributor and services company Cardinal Health (NYSE: CAH) fell short of the market’s revenue expectations in Q1 CY2026, but sales rose 11% year on year to $60.94 billion. Its non-GAAP profit of $3.17 per share was 13.7% above analysts’ consensus estimates.

Is now the time to buy CAH? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Cardinal Health’s first quarter results were received negatively by the market, with revenue growth of 11% year over year failing to meet Wall Street expectations. Management attributed the top-line miss to shifts in product mix within the Pharmaceutical and Specialty Solutions segment, including moderation in GLP-1 drug revenue growth and the impact of Inflation Reduction Act (IRA) pricing adjustments. CEO Jason Hollar emphasized that these headwinds were partially offset by continued strength in specialty and branded pharmaceutical demand, as well as operational resilience in the face of supply chain challenges and winter storm disruptions. The company also absorbed higher expenses from ongoing investments in technology and integration of recent acquisitions.

Looking ahead, Cardinal Health’s increased full-year profit guidance reflects management’s confidence in continued specialty segment expansion, operational efficiencies, and synergy realization from recent M&A activity. CFO Aaron Alt highlighted the ongoing integration of Solaris and ADS, as well as the company’s focus on cost optimization and technology upgrades to drive future margin improvement. Management cautioned that uncertainties remain, particularly around the timing and magnitude of tariff refunds and the evolving regulatory landscape tied to IRA drug pricing reforms, but believe investments in automation and distribution capacity will support sustainable long-term growth.

Key Insights from Management’s Remarks

Management described the quarter as shaped by robust specialty growth, integration of acquisitions, and cost management efforts amid tariff and regulatory headwinds.

• Specialty segment momentum: Cardinal Health’s Pharmaceutical and Specialty Solutions business remained a key growth driver, with specialty revenue up over 20%, led by expanding multi-specialty offerings and the onboarding of new therapies into the SYMEXYS patient support platform. Management cited strong demand from both providers and manufacturers, and the integration of Solaris further strengthened specialty capabilities.

• GLP-1 and IRA effects: While GLP-1 drug revenues increased by more than 30%, growth moderated compared to earlier periods. This uplift was offset by IRA-mandated pricing adjustments, which reduced overall branded drug revenue growth. Management emphasized that these pricing headwinds have limited profit impact due to effective contract renegotiations.

• Acquisition integration progress: The integration of ADS into at-Home Solutions and Solaris into Specialty Alliance advanced on schedule, with the former bringing operational scale and the latter enhancing the company’s specialty network reach. Management highlighted successful onboarding of employees and patients, as well as meaningful synergy realization.

• Cost optimization and supply chain investments: The company continued to execute its simplification and cost efficiency plan, especially in the GMPD segment, which has faced tariff-related headwinds. Investments in automation, technology, and new distribution centers—like the Sacramento facility—were cited as foundation for future growth and margin improvement.

• Tariff and inflationary pressures: Tariffs imposed under the International Emergency Economic Powers Act (IEPA) continued to weigh on the GMPD segment. Management noted the Supreme Court’s recent ruling could result in future refunds, but timing and financial impact remain uncertain. Commodity and fuel cost increases, especially for exam gloves, were seen as manageable but subject to continued monitoring.

Drivers of Future Performance

Cardinal Health’s outlook is driven by specialty expansion, supply chain investments, and navigating industry headwinds like drug pricing reform and tariffs.

• Specialty network and M&A synergies: Management expects specialty growth to outpace the market, supported by ongoing integration of Solaris and ADS, further expansion of the Specialty Alliance, and new physician network partnerships. These initiatives are projected to drive revenue and profit growth into next year.

• Tariff refunds and cost environment: Potential refunds from recently overturned IEPA tariffs could benefit future earnings, but management cautioned on timing and sharing of proceeds with customers. Commodity and fuel cost volatility, particularly in exam gloves and logistics, remain ongoing risks but are viewed as manageable given supply agreements and operational flexibility.

• Regulatory and pricing reforms: The evolving impact of IRA drug pricing changes and the possibility of further fee-for-service contract renegotiations introduce uncertainty. However, management expressed confidence in maintaining distributor economics and sees demographic-driven pharmaceutical demand as a long-term tailwind.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will monitor (1) the pace and profitability of specialty segment expansion and Solaris integration, (2) the timing and magnitude of potential tariff refunds and related customer sharing, and (3) the company’s ability to offset margin pressures from IRA pricing reforms and commodity cost volatility. Progress on supply chain automation and new distribution centers will also be key signposts for future execution.

Cardinal Health currently trades at $192.94, down from $202.82 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.